Literature DB >> 6428341

Immobilization hypercalcemia in acute spinal cord injury treated with etidronate.

G J Merli, G E McElwain, A G Adler, J H Martin, J D Roberts, B Schnall, J F Ditunno.   

Abstract

Hypercalcemia developed in a 30-year-old C5 quadriplegic six months after he received a gunshot wound in the cervical spine. Short-term treatment consisted of fluids and diuretics, but conventional drug therapy for long-term maintenance of normocalcemia was not effective. A regimen of etidronate disodium was then instituted, which resulted in normocalcemia. When use of this drug was discontinued at intervals during the therapy, the hypercalcemia recurred. The patient's condition was maintained on the etidronate regimen until full mobilization occurred, at which time the drug therapy was discontinued and normocalcemia persisted. This case represents, to our knowledge, the first reported success with the use of etidronate in the treatment of hypercalcemia in the immobilized patient with acute spinal injury.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428341

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.

Authors:  H D McIntyre; D P Cameron; S M Urquhart; W E Davies
Journal:  Postgrad Med J       Date:  1989-04       Impact factor: 2.401

2.  Bedside assessment of hypercalcaemia.

Authors:  F P Muldowney; R Freaney; M J McKenna
Journal:  Ir J Med Sci       Date:  1988-11       Impact factor: 1.568

Review 3.  Osteoporosis after spinal cord injury.

Authors:  Sheng-Dan Jiang; Li-Yang Dai; Lei-Sheng Jiang
Journal:  Osteoporos Int       Date:  2005-10-11       Impact factor: 4.507

Review 4.  Vitamin D and spinal cord injury: should we care?

Authors:  J Lamarche; G Mailhot
Journal:  Spinal Cord       Date:  2016-09-20       Impact factor: 2.772

5.  Denosumab for treatment of immobilization-related hypercalcaemia in a patient with advanced renal failure.

Authors:  Esther de Beus; Walther H Boer
Journal:  Clin Kidney J       Date:  2012-10-07

Review 6.  The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain.

Authors:  Giovanni Iolascon; Antimo Moretti
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.